ELVN
Enliven Therapeutics, Inc.
$46.13
+14.30%
$2.8B
No data for this timeframe.
Vol
Market Cap$2.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$1.1B
Inst. Activity16 buys / 6 sells
Insider Activity0B / 9S
Insider Net $-$3.6M
Reddit Sentiment57° Neutral
SEC Reports3
Recent Activity
Jun 12, 2026
SEC
Enliven Therapeutics filed a 424B5 prospectus supplement for a follow-on public offering of 8,933,334 shares of common s
424B5 — Impact 6/10
Jun 11, 2026
SEC
Enliven Therapeutics reported updated positive Phase 1 data for ELVN-001 in CML, showing a 61% overall MMR and 48% MMR a
8-K — Impact 7/10
Jun 5, 2026
SEC
Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven Therapeutics (ELVN), wi
144 — Impact 2/10
Jun 5, 2026
Insider
Kunkel Lori Anne sold 7,779 shares
Director @ $34.28 ($266.7K)
May 18, 2026
Insider
Collins Helen Louise acquired via exercise 5,000 shares
CHIEF MEDICAL OFFICER @ $2.48 ($12.4K)
May 18, 2026
Insider
Collins Helen Louise sold 3,475 shares
CHIEF MEDICAL OFFICER @ $39.53 ($137.4K)
Inst.
Polar Capital Holdings Plc — ADD
5,065,933 shares ($198.6M)
Inst.
Pictet Asset Management Holding — TRIM
929,544 shares ($36.4M)
Price Targets
$60.11
+30.3% upside
Strong Buy
Current $46.13
Low $45.00
Median $60.00
High $80.00
9 analysts
$45.00
$80.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | Stifel | INITIATE | Buy |
| Jun 2, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +6.7% | $-0.43 — $-0.29 | 24% YoY | 3 |
| Next Q | $-0.44 ▲ +6.4% | $-0.48 — $-0.37 | -38% YoY | 3 |
| Current FY | $-1.75 ▲ +4.1% | $-1.98 — $-1.37 | 4% YoY | 4 |
| Next FY | $-2.43 ▼ -2.0% | $-2.90 — $-1.71 | -39% YoY | 4 |
Latest Reports
BEARISH
424B5
6/10
Enliven Therapeutics filed a 424B5 prospectus supplement for a follow-on public offering of 8,933,334 shares of common s
Jun 12, 2026
BULLISH
8-K
7/10
Enliven Therapeutics reported updated positive Phase 1 data for ELVN-001 in CML, showing a 61% overall MMR and 48% MMR a
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $267.7M | — |
| Polar Capital Holdings Plc | $198.6M | ADD |
| BlackRock, Inc. | $144.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $85.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Kunkel Lori | SELL | $266.7K |
| May 18, 2026 | Collins Helen | M | $12.4K |
| May 18, 2026 | Collins Helen | SELL | $137.4K |
| Apr 17, 2026 | Collins Helen | M | $12.4K |
| Apr 17, 2026 | Collins Helen | SELL | $6.4K |
Reddit Sentiment
57°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.1B total value (28,645,986 shares) as of 2026-Q1. Top holders: NOMURA, FMR, Polar. Net buying activity: 16 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 6,829,246 | $267.7M | 24.2% | — |
| 3 | Polar Capital Holdings Plc | 5,065,933 | $198.6M | 18.0% | ADD +44.2% |
| 4 | BlackRock, Inc. | 3,684,707 | $144.4M | 13.1% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,168,162 | $85.0M | 7.7% | — |
| 6 | CITADEL ADVISORS LLC | 1,743,915 | $68.4M | 6.2% | — |
| 7 | STATE STREET CORP | 1,091,106 | $42.8M | 3.9% | — |
| 8 | Pictet Asset Management Holding SA | 929,544 | $36.4M | 3.3% | TRIM -28.7% |
| 9 | BAKER BROS. ADVISORS LP | 905,191 | $35.5M | 3.2% | DOUBLED +233.5% |
| 10 | DIMENSIONAL FUND ADVISORS LP | 681,715 | $26.7M | 2.4% | ADD +70.9% |
| 11 | MORGAN STANLEY | 518,572 | $20.3M | 1.8% | ADD +25.9% |
| 12 | GOLDMAN SACHS GROUP INC | 473,115 | $18.5M | 1.7% | — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 360,577 | $14.1M | 1.3% | — |
| 14 | VANGUARD PORTFOLIO MANAGEMENT LLC | 330,964 | $13.0M | 1.2% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 312,763 | $12.3M | 1.1% | — |
| 16 | BALYASNY ASSET MANAGEMENT L.P. | 310,025 | $12.2M | 1.1% | NEW |
| 17 | JENNISON ASSOCIATES LLC | 309,180 | $12.1M | 1.1% | NEW |
| 18 | ALLIANCEBERNSTEIN L.P. | 771,885 | $11.9M | 1.1% | — |
| 19 | Woodline Partners LP | 301,673 | $11.8M | 1.1% | TRIM -72.7% |
| 20 | D. E. Shaw & Co., Inc. | 193,531 | $7.6M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | ADD | 3,513,680 | 5,065,933 | +44.2% | $198.6M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 1,303,235 | 929,544 | -28.7% | $36.4M | 2026-Q1 |
| BAKER BROS. ADVISORS LP | DOUBLED | 271,406 | 905,191 | +233.5% | $35.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 398,893 | 681,715 | +70.9% | $26.7M | 2026-Q1 |
| MORGAN STANLEY | ADD | 411,823 | 518,572 | +25.9% | $20.3M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 310,025 | — | $12.2M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | NEW | — | 309,180 | — | $12.1M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 18,949 | 160,577 | +747.4% | $6.3M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 35,580 | 66,940 | +88.1% | $2.6M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 24,720 | 61,752 | +149.8% | $2.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 32,711 | 45,162 | +38.1% | $1.8M | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 60,415 | 30,101 | -50.2% | $1.2M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 20,398 | 28,415 | +39.3% | $1.1M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 10,800 | 15,300 | +41.7% | $599.8K | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEAR_EXIT | 1,671,724 | 11,000 | -99.3% | $431.2K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | ADD | 589 | 1,044 | +77.2% | $40.9K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 635 | 844 | +32.9% | $33.1K | 2026-Q1 |
| CWM, LLC | ADD | 94 | 142 | +51.1% | $5.6K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | 23,800 | 97,747 | +310.7% | $3.8K | 2026-Q1 |
| Blackstone Inc. | EXIT | 954,946 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Capital Research Global Investors | EXIT | 1,304,346 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 1,504,601 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 1,040,410 | 1,504,601 | +44.6% | $23.2M | 2025-Q4 |
| Blackstone Inc. | TRIM | 1,320,592 | 954,946 | -27.7% | $14.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 258,384 | 411,823 | +59.4% | $6.3M | 2025-Q4 |
11 unique insiders with 30 transactions. Net insider value: -$3.6M ($0.00 bought, $3.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Kunkel Lori Anne | Director | SELL | 7,779 | $34.28 | $266.7K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 5,000 | $2.48 | $12.4K |
| May 18, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 3,475 | $39.53 | $137.4K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 5,000 | $2.48 | $12.4K |
| Apr 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 140 | $45.81 | $6.4K |
| Mar 25, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 40,000 | $2.48 | $99.2K |
| Mar 25, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 40,000 | $35.10 | $1.4M |
| Mar 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 5,000 | $2.48 | $12.4K |
| Mar 17, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 5,000 | $27.76 | $138.8K |
| Mar 10, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 10,129 | $2.48 | $25.1K |
| Mar 10, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 10,129 | $30.19 | $305.8K |
| Mar 9, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | EXERCISE | 29,871 | $2.48 | $74.1K |
| Mar 9, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | SELL | 29,871 | $30.02 | $896.8K |
| Mar 6, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | SELL | 10,000 | $29.58 | $295.8K |
| Feb 12, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | AWARD | 18,750 | — | — |
| Feb 12, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | AWARD | 112,500 | — | — |
| Feb 12, 2026 | Gupta Rishi | Director | AWARD | 33,989 | — | — |
| Feb 12, 2026 | Garland J. Scott | Director | AWARD | 1,427 | — | — |
| Feb 12, 2026 | Derynck Mika K | Director | AWARD | 17,126 | — | — |
| Feb 12, 2026 | Bauer Jake | Director | AWARD | 17,126 | — | — |
| Feb 12, 2026 | Ballal Rahul D. | Director | AWARD | 17,126 | — | — |
| Feb 12, 2026 | Heyman Richard A. | Director | AWARD | 19,234 | — | — |
| Feb 12, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | AWARD | 25,000 | — | — |
| Feb 12, 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | AWARD | 150,000 | — | — |
| Feb 12, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | AWARD | 25,000 | — | — |
| Feb 12, 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | AWARD | 150,000 | — | — |
| Feb 12, 2026 | Kunkel Lori Anne | Director | AWARD | 17,126 | — | — |
| Feb 12, 2026 | Patel Anish | CHIEF OPERATING OFFICER | AWARD | 20,000 | — | — |
| Feb 12, 2026 | Patel Anish | CHIEF OPERATING OFFICER | AWARD | 120,000 | — | — |
| Feb 6, 2026 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | SELL | 5,000 | $29.04 | $145.2K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
424B5
6/10
Enliven Therapeutics filed a 424B5 prospectus supplement for a follow-on public offering of 8,933,33
Jun 12, 2026
BULLISH
8-K
7/10
Enliven Therapeutics reported updated positive Phase 1 data for ELVN-001 in CML, showing a 61% overa
Jun 11, 2026
NEUTRAL
144
2/10
Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven The
Jun 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$60.11 mean target
+30.3% upside
Strong Buy (1.00)
$45.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $46.13 |
| Target Low | $45.00 |
| Target Mean | $60.11 |
| Target Median | $60.00 |
| Target High | $80.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.43 | $-0.29 | 23.8% | +6.7% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.44 | $-0.48 | $-0.37 | -37.5% | +6.4% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.75 | $-1.98 | $-1.37 | 4.4% | +4.1% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-2.43 | $-2.90 | $-1.71 | -38.9% | -2.0% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.373 | |
| 7d ago | $-0.345 | -0.028 |
| 30d ago | $-0.400 | +0.027 |
| 60d ago | $-0.420 | +0.047 |
| 90d ago | $-0.560 | +0.187 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | Stifel | INITIATE | — | Buy |
| Jun 2, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
57°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 28, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Mar 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Apr 16, 2026
short_volume
Short Volume: ELVN — 55.2% short (0.4M / 0.8M)
Short: 427,653 | Exempt: 0 | TRF Vol: 774,451 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: ELVN — 15,603 shares ($0.6M) failed to deliver
Settlement: 20260406, Price: $38.83, FTD Value: $605,864.49, ENLIVEN THERAPEUTICS INC COM
Apr 2, 2026
short_interest
FTD: ELVN — 15,707 shares ($0.6M) failed to deliver
Settlement: 20260402, Price: $37.79, FTD Value: $593,567.53, ENLIVEN THERAPEUTICS INC COM
Mar 12, 2026
earnings_calendar
ELVN Q4 2025 Earnings After Market Close — 2026-03-12
Mar 11, 2026
earnings_calendar
ELVN Q4 2025 Earnings After Market Close — 2026-03-11
Mar 5, 2026
short_interest
FTD: ELVN — 23,773 shares ($0.7M) failed to deliver
Settlement: 20260305, Price: $29.98, FTD Value: $712,714.54, ENLIVEN THERAPEUTICS INC COM
Mar 4, 2026
short_interest
FTD: ELVN — 30,016 shares ($0.9M) failed to deliver
Settlement: 20260304, Price: $28.75, FTD Value: $862,960, ENLIVEN THERAPEUTICS INC COM
Mar 3, 2026
short_interest
FTD: ELVN — 23,981 shares ($0.7M) failed to deliver
Settlement: 20260303, Price: $29.50, FTD Value: $707,439.5, ENLIVEN THERAPEUTICS INC COM
Feb 20, 2026
short_interest
FTD: ELVN — 28,794 shares ($0.8M) failed to deliver
Settlement: 20260220, Price: $26.16, FTD Value: $753,251.04, ENLIVEN THERAPEUTICS INC COM
Feb 18, 2026
short_interest
FTD: ELVN — 59,914 shares ($1.6M) failed to deliver
Settlement: 20260218, Price: $26.13, FTD Value: $1,565,552.82, ENLIVEN THERAPEUTICS INC COM